前往化源商城

136-70-9 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: 5mMGluc_INS1E_InsulinRelease_40mMGluc_SP
Protocol: N/A
Comment: N/A
Activity at 2 uMActivity at 10 uM
1.051.35
-1.2-2.5
0.6-0.4
1.10
2.050.15
-1.2-0.5
1.150.95
-0.4-2
0.7-1.2
-2.3-2.4
0.50.9
1.91.9
-1.16.2
-0.9-0.3
2.24.1
2.61.85
35.9
2.60.5
17.6
0.80.8
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A4437
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-8.32134.95490.64234-4.834640 0 0 0 0 0 1-4.4443-2.77887.36895.36932.33973.33831.6715-4.4443QC'd by Sytravon0
Inhibitor2.391969.704984Complete curve; high efficacy-5.62130.90.993-69.49290.212-1.10 0 0 0 0 0 0-66.6604-0.25131.2197-5.3806-9.9311-37.162-53.3921-66.6604QC'd by Sytravon0
Inhibitor9.522176.407442Partial curve; high efficacy-5.02131.1110.9951-75.90940.498-2.10 0 0 0 0 0 0-66.59123.4283-1.6815-1.5622-0.1199-13.7121-41.7015-66.5912QC'd by Sytravon0
Inactive0-4.52131.75290.9212-24.98775.540 0 0 0 0 0 0-17.48977.36232.46169.84163.36053.96510.8896-17.4897QC'd by Sytravon0
Inhibitor1.5092115.26487Complete curve; high efficacy-5.82131.46410.9934-109.85685.4073-1.10 0 0 0 0 0 0-110.2979-0.81499.86343.518-7.3368-73.6123-100.848-110.2979QC'd by Sytravon0
Inhibitor1.6933117.978187Complete curve; high efficacy-5.77134.50450.9912-112.735.2481-1.10 0 0 0 0 0 0-115.265815.93722.4103-1.24092.2518-88.9575-109.7932-115.2658QC'd by Sytravon0
Inhibitor4.772481.295643Partial curve; high efficacy-5.321310.9946-78.60572.6899-2.10 0 0 0 0 0 0-71.671-0.64476.43020.1885-3.4582-24.3313-55.7062-71.671QC'd by Sytravon0
Inhibitor7.563794.395183Complete curve; high efficacy-5.12134.95490.9967-94.6258-0.2307-1.10 0 0 0 0 0 0-93.87483.4317-2.5012-1.7201-2.44552.6182-85.3984-93.8748QC'd by Sytravon0
Inhibitor2.683765.029784Complete curve; high efficacy-5.57134.0950.989-65.3833-0.3537-1.10 0 0 0 0 0 0-70.4739-2.312-0.8042-1.22813.0628-22.6396-60.696-70.4739QC'd by Sytravon0
Inhibitor7.563757.206142Partial curve; partial efficacy-5.12131.62590.9942-54.13193.0742-2.20 0 0 0 0 0 0-52.30876.2072.82521.47620.0987-3.9796-35.0702-52.3087QC'd by Sytravon0
Inhibitor1.198874.619785Complete curve; high efficacy-5.92131.13410.9933-70.92043.6993-1.10 0 0 0 0 0 0-71.49064.2219-0.18864.5237-17.1469-46.9199-63.4145-71.4906QC'd by Sytravon0
Inhibitor2.1317118.451686Complete curve; high efficacy-5.67132.72020.993-110.08868.3631-1.10 0 0 0 0 0 0-116.12727.57825.10285.881412.5352-56.6231-102.2879-116.1272QC'd by Sytravon0
Inhibitor2.1317122.703187Complete curve; high efficacy-5.67132.40640.9787-115.72726.9759-1.10 0 0 0 0 0 0-122.07513.858917.443-6.083311.7009-62.2871-106.7609-122.0751QC'd by Sytravon0
Inhibitor6.7412121.082984Complete curve; high efficacy-5.17134.0950.9954-126.4671-5.3842-1.10 0 0 0 0 0 0-126.975-0.8069-3.4445-2.4548-11.8834-10.2564-113.7668-126.975QC'd by Sytravon0
Inhibitor4.772486.82744Partial curve; high efficacy-5.321310.9941-85.3831.444-2.10 0 0 0 0 0 0-78.6992-2.43161.8612-0.004-1.8987-28.5107-58.6303-78.6992QC'd by Sytravon0
Inhibitor7.5637125.15484Complete curve; high efficacy-5.12133.92950.9979-122.58722.5668-1.10 0 0 0 0 0 0-123.07953.09863.12671.8871-2.10935.2605-101.0355-123.0795QC'd by Sytravon0
Inhibitor0.6741119.919989Complete curve; high efficacy-6.17131.37230.9986-109.745410.1745-1.10 0 0 0 0 0 0-110.8548.84597.74156.7576-35.5397-88.9969-106.7803-110.854QC'd by Sytravon0
Inhibitor6.7412115.981384Complete curve; high efficacy-5.17132.30310.9963-113.59672.3846-1.10 0 0 0 0 0 0-113.37-1.2322-1.59845.85995.7708-6.0722-86.9448-113.37QC'd by Sytravon0
Inhibitor1.5092114.050988Complete curve; high efficacy-5.82131.96730.9946-113.91580.1351-1.10 0 0 0 0 0 0-113.0117-0.8223-4.0553-2.3728-1.6822-81.3904-111.2484-113.0117QC'd by Sytravon0
Inhibitor8.486660.792742Partial curve; partial efficacy-5.07132.40640.9868-57.96392.8287-2.20 0 0 0 0 0 0-56.54736.87814.87661.3348-2.20081.3516-39.1581-56.5473QC'd by Sytravon0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2D6395
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (quinidine) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-7.260.70.983122040 0 0 0 0 0 0 018.72430.75090.74030.16150.22082.57129.062412.490518.7243QC'd by Labotest0
Inactive00043.08132.90954.18193.06831.54751.9993-1.48293.82823.0813QC'd by Labotest0
Inhibitor10.96462.697110Partial curve; high efficacy; poor fit-4.964.95490.998-66.9977-4.3007-2.31 0 0 0 0 0 0 0-65.7875-42.8846-3.6636-4.8429-3.3836-3.8623-4.4736-41.4229-65.7875QC'd by Microsource0
Inhibitor38.901833.850110Partial curve; partial efficacy; poor fit-4.414.95490.924-33.35010.5-2.40 0 0 0 0 0 0 0-29.0418-1.55510.52060.875-1.2476-0.5605-1.80927.4199-29.0418QC'd by SIGMA0
Inhibitor1.737781.229885Complete curve; high efficacy-5.761.96730.9976-79.95641.2734-1.10 0 0 0 0 0 0 0-78.3324.47950.76060.0181-0.701-3.7995-49.0322-80.0522-78.332QC'd by Tocris0
Inhibitor34.671337.231710Partial curve; partial efficacy; poor fit-4.462.35310.9195-37.23170-2.40 0 0 0 0 0 0 0-28.52643.96925.0423-3.0201-3.1048-1.1738-0.8348-2.4447-28.5264QC'd by Microsource0
Inhibitor15.487171.27341Partial curve; high efficacy-4.811.44870.9928-70.41130.8617-2.10 0 0 0 0 0 0 0-61.76430.28531.9381-1.2811-0.34364.6186-4.2001-27.4432-61.7643QC'd by GVK0
Inhibitor0.218891.972890Complete curve; high efficacy-6.660.80.9894-90.01021.9626-1.10 0 0 0 0 0 0 0-83.87692.77070.8657-14.6874-27.4321-55.0254-79.0233-92.6031-83.8769QC'd by Prestwick Chemical; Inc.0
Inhibitor34.671345.828810Single point of activity-4.462.35310.9938-45.82880-30 0 0 0 0 0 0 0-35.0976-0.4182-0.112-0.91482.1786-0.5211-0.77-3.3082-35.0976QC'd by Vitas0
Inhibitor13.8029116.598142Partial curve; high efficacy-4.860.70.9704-115.4741.1242-2.10 0 0 0 0 0 0 0-87.4803-1.2071.2781-1.1552-1.0641-0.761-34.877-47.6739-87.4803QC'd by Vitas0
Inhibitor19.497171.169541Partial curve; high efficacy-4.712.33320.9649-71.6292-0.4597-2.10 0 0 0 0 0 0 0-66.007-7.5073.5896-6.58233.21022.04942.4442-17.4355-66.007QC'd by Enzo0
Inactive0004-0.33970.68341.1935-3.1601-7.1353-6.692-3.5353-4.6055-0.3397QC'd by Microsource0
Inhibitor38.901899.707710Single point of activity-4.412.90230.9979-103.2475-3.5398-30 0 0 0 0 0 0 0-78.9754-2.6538-1.9475-2.4198-3.036-5.7354-4.4174-6.1242-78.9754QC'd by Labotest0
Inactive00040.55794.29663.86970.9141.57842.77632.2827-0.27460.5579QC'd by Microsource0
Inactive0004-2.28934.50485.93892.79056.12561.13645.75735.7586-2.2893QC'd by Tocris0
Inhibitor12.301842.282721Partial curve; partial efficacy-4.912.33320.9667-45.1528-2.8702-2.20 0 0 0 0 0 0 0-43.5551-8.1379-5.4062-0.92150.1464-0.2747-3.1761-22.7908-43.5551QC'd by Labotest0
Inactive00042.7074-0.37290.3242.07662.64641.1615-0.70884.47812.7074QC'd by Prestwick0
Inactive0004-1.99643.70481.65273.62083.19225.03624.9342-1.7586-1.9964QC'd by Microsource0
Inactive0-6.360.80.89615-7.047740 0 0 0 0 0 0 04.9227-4.8515-7.6164-8.7898-3.26990.29170.34185.50584.9227QC'd by VitasInactive00
Inhibitor3.4671109.162545Partial curve; high efficacy-5.460.90.9982-103.53135.6312-2.10 0 0 0 0 0 0 0-96.39795.98693.1773.47834.7559-9.3266-39.4946-74.1667-96.3979QC'd by Enzo0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: GSK3b_inh_pretreated_Viability_ATP_HCT116_SP
Protocol: N/A
Comment: N/A
Activity at 0.2 uMActivity at 2 uMActivity at 20 uM
-0.8-526.1
-4.15-1.1-7.2
-2-0.5-15.6
-6.4-13.6-13.4
-1.71.452.2
15.440.170
6.53.440.5
3.15-4.5-4.75
4.1-1.210.9
1.35-138.85
-0.51.6-14.3
-11.3-1039.1
7.0714.830.37
-1.8-1.57.5
19.1-3.9-10.9
13.90-5.5
-11.87.77.7
-10.05-4.15-2.95
5.51.32.6
-0.2-2.5-8.8
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2C9536
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix supplemented with 0.4% Bovine Serum Albumin was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (sulfaphenazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at 37C for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inhibitor21.317485.520741Partial curve; high efficacy-4.67133.19250.957-74.520711-2.10 0 0 0 0 0 0-71.26736.65818.66165.03429.029624.68310.5948-71.2673QC'd by Microsource0
Inactive00040.31867.0625.1975.69257.23591.2670.52010.3186QC'd by Microsource0
Inhibitor7.563793.544743Partial curve; high efficacy-5.12131.92820.9984-89.27954.2653-2.10 0 0 0 0 0 0-87.52897.16565.07882.79792.1575-3.7741-60.4613-87.5289QC'd by Tocris0
Inhibitor26.83748.635610Single point of activity-4.57132.24810.9788-42.84845.7872-30 0 0 0 0 0 0-35.46775.96295.47962.709210.27554.6543-0.1967-35.4677QC'd by NCI0
Inhibitor8.4866130.766843Partial curve; high efficacy-5.071310.9992-119.896710.8701-2.10 0 0 0 0 0 0-102.475811.946611.24277.15545.0781-16.0537-65.0649-102.4758QC'd by BIOMOL0
Inhibitor5.354799.189644Partial curve; high efficacy-5.27130.90.9888-96.57122.6185-2.10 0 0 0 0 0 0-87.001-0.2592-1.6376.8143-4.5159-32.2161-61.4841-87.001QC'd by BIOMOL0
Inactive0-4.67132.33320.6923-15.1448-0.540 0 0 0 0 0 0-13.8707-3.7401-1.27785.1005-4.69041.916-3.5213-13.8707QC'd by InterBioScreen0
Inhibitor25.401256.202240Partial curve; partial efficacy-4.59514.50450.9727-57.7888-1.5865-2.20 0 0 0 0 0 0 0-57.6748-1.4876-4.4957-6.22962.86763.1906-3.7494-18.0858-57.6748QC'd by LightBiologicalsInhibitor40.258241.12110Single point of activity-4.39512.95230.943-42.7254
Inhibitor7.563797.471243Partial curve; high efficacy-5.12131.92820.9955-91.45176.0195-2.10 0 0 0 0 0 0-89.13426.42811.19024.98681.8065-2.3315-62.2028-89.1342QC'd by Tocris0
Inhibitor21.317476.663841Partial curve; partial efficacy-4.67131.24750.9713-70.16386.5-2.20 0 0 0 0 0 0-53.059711.862810.1962-0.30794.2931.9517-17.9254-53.0597QC'd by SigmaAldrich0
Inhibitor26.837101.665640Partial curve; high efficacy-4.57131.59360.9916-96.27045.3952-2.10 0 0 0 0 0 0-73.31095.62388.78586.24482.4666-0.9326-13.5438-73.3109QC'd by Tocris0
Inhibitor3.790887.146544Partial curve; high efficacy-5.42130.80.9942-85.19521.9512-2.10 0 0 0 0 0 0-78.88451.4625-1.87161.6032-10.9203-35.4628-58.552-78.8845QC'd by Tocris0
Inhibitor37.9083129.914810Single point of activity-4.42134.95490.9896-129.29750.6173-30 0 0 0 0 0 0-114.6255-1.4437-2.5082-0.90198.8381-4.54583.1106-114.6255QC'd by SigmaAldrich0
Inhibitor26.837109.062140Partial curve; high efficacy-4.57131.34370.9459-109.3538-0.2917-2.10 0 0 0 0 0 0-82.84382.53255.07320.78280.5149-19.3744-20.4297-82.8438QC'd by Bosche0
Inactive0-4.412.90230.8395-17.3952-0.540 0 0 0 0 0 0 0-13.246-3.84691.9539-0.2562-2.65371.4770.7446-0.9487-13.246QC'd by ACC0
Inactive0-8.363.1320.36283-4.516440 0 0 0 0 0 0 02.109-4.1803-1.83775.2557-1.05048.3001-3.10856.7452.109QC'd by Pharmaron0
Inactive00040.5041-8.57852.70450.1138-10.58420.93582.08840.5041QC'd by Toronto Research0
Inhibitor44.493235.276510Single point of activity-4.35173.67720.8478-34.72730.5492-30 0 0 0 0 0 0 0-32.3137-1.4989-3.7044-1.139-0.492412.1946-1.1884-3.139-32.3137QC'd by RTI0
Inactive00046.63087.63316.0247.39860.22633.18743.42856.6308QC'd by Tocris0
Inactive00045.326112.576410.112211.536311.2627.1953.95915.3261QC'd by NCGCChem0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-SARS-CoV-2-cytotox-48hr
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 h at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin).
6. Incubation. Incubate at for 48h at 37C 5% CO2
7. Reagent. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
8. Incubation. Incubate for 15 min at room temperature.
9. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells without cells (media only control) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Cytotoxic2.511989.96385Complete curve; high efficacy-5.62.40640.9988-81.9638-1.10 0 0 0-81.02564.3424-26.1944-82.8623-81.0256QC'd by MedChem Express
Cytotoxic3.162394.537785Complete curve; high efficacy-5.54.50450.9999-94.32250.2153-1.10 0 0 0-94.7013-0.2373-13.1526-93.6408-94.7013QC'd by SIGMA
Cytotoxic2.818494.81785Complete curve; high efficacy-5.552.04790.9999-95.8221-1.005-1.10 0 0 0-95.0616-6.2542-35.3146-94.5292-95.0616QC'd by APExBIO
Cytotoxic2.818490.520785Complete curve; high efficacy-5.553.06540.9989-88.52072-1.10 0 0 0-86.88350-24.056-89.9601-86.8835QC'd by MedChem Express
Cytotoxic5.623496.974284Complete curve; high efficacy-5.254.0951-95.47421.5-1.10 0 0 0-95.85761.65590-94.7507-95.8576QC'd by SynKinase
Cytotoxic3.981196.100684Complete curve; high efficacy-5.44.50451-95.10061-1.10 0 0 0-94.91080.5692-4.2795-94.8159-94.9108QC'd by Tocris
Cytotoxic2.511977.656384Complete curve; high efficacy-5.62.04790.9997-80.7421-3.0858-1.10 0 0 0-80.0369-5.0715-39.0219-77.613-80.0369QC'd by Microsource
Cytotoxic7.943399.498683Complete curve; high efficacy-5.14.95490.9997-96.99862.5-1.10 0 0 0-96.8051.23063.5418-95.9316-96.805QC'd by MedChem Express
Cytotoxic7.079597.835883Complete curve; high efficacy-5.154.95490.9993-95.83582-1.10 0 0 0-95.644503.4249-95.1788-95.6445QC'd by Tocris
Cytotoxic7.079597.375183Complete curve; high efficacy-5.154.0951-97.37510-1.10 0 0 0-97.18070-0.6843-95.5282-97.1807QC'd by MedChem Express
Cytotoxic7.0795102.439983Complete curve; high efficacy-5.151.69240.9998-100.43992-1.10 0 0 0-96.76290-9.8984-85.0051-96.7629QC'd by MedChem Express
Cytotoxic7.079596.356883Complete curve; high efficacy-5.154.95491-96.35680-1.10 0 0 0-96.164400-95.5939-96.1644QC'd by MedChem Express
Cytotoxic7.079593.612783Complete curve; high efficacy-5.154.95491-93.61270-1.10 0 0 0-93.425800-92.8807-93.4258QC'd by MedChem Express
Cytotoxic8.912597.135783Complete curve; high efficacy-5.054.95491-97.13570-1.10 0 0 0-96.941800-94.9322-96.9418QC'd by APExBIO
Cytotoxic8.9125105.03483Complete curve; high efficacy-5.051.64360.9999-100.0345-1.10 0 0 0-94.72923.0536-3.9173-76.9038-94.7292QC'd by Glixx
Cytotoxic1091.303782Complete curve; high efficacy-52.18761-85.80375.5-1.10 0 0 0-84.12124.86462.5388-67.7158-84.1212QC'd by SIGMA
Cytotoxic1098.125282Complete curve; high efficacy-52.84730.9999-97.62520.5-1.10 0 0 0-96.850400-83.9555-96.8504QC'd by Cayman
Cytotoxic11.220293.877282Complete curve; high efficacy-4.952.40640.9998-92.87721-1.10 0 0 0-91.056100-72.1776-91.0561QC'd by Selleck
Cytotoxic0.891360.234867Complete curve; partial efficacy-6.053.51170.9985-93.1767-32.9418-1.20 0 0 0-93.5509-51.1212-90.8041-91.9137-93.5509QC'd by Selleck
Cytotoxic0.794356.680267Complete curve; partial efficacy-6.13.92950.9999-91.2497-34.5695-1.20 0 0 0-91.0675-40.2642-90.3425-90.8279-91.0675QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3253168
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1978
Volume: 21
Issue: 9
First Page: 922
Last Page: 930
DOI: 10.1021/jm00207a015
Standard TypeStandard RelationStandard Value
Intrinsic activity=0.75
Intrinsic activity=0.87
Intrinsic activity=0.71
Intrinsic activity=0.27
Intrinsic activity=1.1
Intrinsic activity=0.64
Intrinsic activity=1.1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: hNCI-H716_GLP1_Secretion_SP
Protocol: N/A
Comment: N/A
Activity at 2 uMActivity at 10 uM
0.4-0.1
2.11.1
0.31
-1.90.3
-2.42
1.63.4
-3.4-1.5
0.51.4
1.38.5
1.13.3
-0.5-0.7
2.32.6
2.80.1
2.26
0.83.1
2.6-0.1
-21-21
0.4-1.1
10.5
01.9
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3253167
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1978
Volume: 21
Issue: 9
First Page: 922
Last Page: 930
DOI: 10.1021/jm00207a015
Standard TypeStandard RelationStandard Value
pKb<3.7
pKb<3.7
pKb=3.7
pKb=5.07
pKb=4.55
pKb=4.46
pKb=4.74
pKb=5.06
pKb=4.66
pKb=4.19
pKb<3.7
pKb=7.85
pKb=6.17
pKb=5.04
pKb=4.41
pKb=4.28
pKb=6.17
pKb=4.08
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: VEGF_ADSC_ECFC_Angio_CD31_TubeArea_SP
Protocol: N/A
Comment: N/A
Activity at 2 uMActivity at 10 uM
-6.5-1.2
6.2-8.1
-22.1-8.2
-5.67.4
-6.63.5
2.7-8.6
5.2-10.7
21.82.7
-10.59.6
-13.31.9
-10.4-4.4
2.314.1
2.12.1
1.45.9
5.70.3
-7.1-9.6
-5.8-11.2
-1-36.8
-4.2-12.4
-12.2-9
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: Basal_Viability_ATP_SW480_SP
Protocol: N/A
Comment: N/A
Activity at 0.2 uMActivity at 2 uMActivity at 20 uM
18.418.217.1
16.67.823.6
-2.53.616.2
19.434.522.8
15.624.6125.8
48.875.790.3
27.314.323.3
6.1528.859.1
21.212.649.7
-6.47.611.9
0.2-0.4-16.3
3-1.5-2.4
46.1-3.51.7
10.115.25.3
-36.65.815
13.2-5.516.6
-28.60.2-24.3
1.4-13.240.9
12.3534.45132.2
1320.8-14.2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: TRND-SARS-CoV-2-PP
Protocol: PROTOCOL TABLE (format as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 hr at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of SARS-CoV-2-S pseudotyped particles. [a] PPs are produced with murine leukemia virus pseudotyping. [b] SARS-CoV-2-S is Wuhan-Hu-1 sequence (BEI #NR-52420) with C-terminal 19 amino acid truncation.
6. Centrifuge. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubation. Incubate at for 48 hr at 37C 5% CO2
8. Centrifuge. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Reagent. Dispense 4 uL/well of Bright-Glo Luciferase detection reagent (Promega #E2620).
10. Incubation. Incubate for 5 min at room temperature.
11. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing SARS-CoV-2-S PP as 100%, and wells containing bald PP (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Inhibitor0.707934.828810Complete curve; partial efficacy; poor fit-6.154.95490.7525-34.81130.0174-1.40 0 0 0-43.6793-3.7355-37.8905-22.6342-43.6793QC'd by MedChem Express
Inhibitor35.481336.764810Single point of activity-4.452.40640.8748-40.7648-4-30 0 0 0-31.8873-11.45960-6.0521-31.8873QC'd by Pharmaron
Inhibitor39.810740.392710Single point of activity-4.44.44950.7948-48.5731-8.1804-30 0 0 0-41.7275-5.1127-20.8986-3.4837-41.7275QC'd by FLUKA
Inhibitor39.810736.302110Single point of activity-4.44.44950.9302-39.3021-3-30 0 0 0-33.1684-8.76590-0.1246-33.1684QC'd by Prestwick
Inhibitor1091.825410Partial curve; high efficacy; poor fit-53.92951-91.32540.5-2.31 0 0 0-91.1431-30.0380-57.0259-91.1431QC'd by APExBIO
Inhibitor39.810788.872610Single point of activity-4.44.95490.9981-87.87261-30 0 0 0-75.3105003.3645-75.3105QC'd by Microsource
Inhibitor39.810739.07410Single point of activity-4.44.95490.9982-38.5740.5-30 0 0 0-32.9783001.4313-32.9783QC'd by Carbosynth
Inhibitor17.782845.659310Partial curve; partial efficacy; poor fit-4.751.96730.9887-54.3257-8.6664-2.40 0 0 0-50.2467-11.0836-6.8054-21.6158-50.2467QC'd by TargetMol
Inhibitor39.810774.978610Single point of activity-4.44.44950.9815-77.9786-3-30 0 0 0-65.3989-8.931700-65.3989QC'd by MedChem Express
Inhibitor39.810735.78810Single point of activity-4.44.44950.945-39.8408-4.0529-30 0 0 0-34.034-8.1712-5.8755-0.0441-34.034QC'd by Adooq
Inhibitor19.952698.547510Partial curve; high efficacy; poor fit-4.71.96730.9936-101.5475-3-2.30 0 0 0-90.5058-6.67020-28.4282-90.5058QC'd by MedChem Express
Inhibitor39.810794.209610Partial curve; high efficacy; poor fit-4.44.44950.9731-106.3898-12.1802-2.30 0 0 0-90.4675-6.8168-21.693-10.2877-90.4675QC'd by Axon Medchem
Inhibitor39.810768.339410Single point of activity-4.44.95490.8933-61.33947-30 0 0 0-51.53290021.3412-51.5329QC'd by MedChem Express
Inhibitor11.220245.057510Partial curve; partial efficacy; poor fit-4.951.85790.9996-42.55752.5-2.41 0 0 0-40.794-21.67980-20.0057-40.794QC'd by MedChem Express
Inhibitor22.3872113.332310Partial curve; high efficacy; poor fit-4.651.69241-111.33232-2.31 0 0 0-91.8583-33.87930-25.3979-91.8583QC'd by Microsource
Inhibitor7.079544.4210Single point of activity-5.154.95490.6152-48.42-4-30 0 0 0-44.8333-14.7954-20.3760-44.8333QC'd by SIGMA
Inhibitor39.810732.918510Single point of activity-4.44.95490.6127-36.9185-4-30 0 0 0-32.01542.7163-20.08280-32.0154QC'd by Selleck
Inhibitor39.810751.184410Single point of activity-4.44.44951-51.18440-30 0 0 0-42.6537000-42.6537QC'd by MedChem Express
Inhibitor1058.179910Partial curve; partial efficacy; poor fit-53.51170.9887-59.1799-1-2.40 0 0 0-59.8069-4.87472.0564-35.7833-59.8069QC'd by DC Chemicals
Inhibitor39.810740.290110Single point of activity-4.44.44950.7334-45.6865-5.3964-30 0 0 0-38.9054-16.4277-13.0282-1.1636-38.9054QC'd by Adooq
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: Basal_Viability_ATP_HCT116_SP
Protocol: N/A
Comment: N/A
Activity at 0.2 uMActivity at 2 uMActivity at 20 uM
3.22.511.9
32.316.2-36.7
-4.92.5-0.4
-33.90.62.4
-2.32.438.9
-27.323.859.6
1.12.134.3
8.5-0.8-5.3
1.44.933.6
8-0.11.5
-32.6-5.40.6
-15.8-1211.7
10.79.1525.9
40.810.8
-4.66.89.4
-1.2-3.6-6.4
2.12.20.6
-13.8-26.98.9
-26.2-2.810
-31.84.26.6
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ADME-HLM1
Protocol: Microsomal Stability Assay
The substrate depletion method, also called the in vitro t1/2 method was used to analyze test compounds. Incubation and liquid handling were carried out using a previously described method (Shah et al., 2016). Briefly, each reaction mixture (110 muL) consisted of a test article (1 muM), human liver microsomes (0.5 mg/mL), and NADPH regenerating system in phosphate buffer at pH 7.4. Samples were incubated in 384-well plates at 37 degrees C for 0, 5, 10, 15, 30 and 60 min. At each time point, 10 muL of the incubation mixture was aspirated into another 384-well plate which contained cold acetonitrile (ACN) with internal standard (albendazole). All plates were centrifuged at 3000 rpm for 20 min at 4 degrees C, and the supernatants were transferred to a 384-well injection plate. Sample quantification and analysis was performed using a previously described method (Shah et al., 2016, Siramshetty et al., 2020). Compounds are classified as Unstable (t1/2 < 30 min) or stable (t1/2 > 30 min)

Reference:
1: Shah, P. et al. An Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software. Drug Metab Dispos 44, 1653-1661 (2016).
2: Siramshetty et al. Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models. Sci Rep 26;10(1):20713 (2020).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The interpretations presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Phenotype compound classification is based on the half-life observed. Compound is "stable" if half-life (t1/2) is more than 30 minutes (class = 0); "unstable" if t1/2 is less than 30 minutes (class = 1). For this assay, stable compounds are ranked higher than compounds that are unstable.
2. PUBCHEM_ACTIVITY_OUTCOME corresponds to the phenotype observed. For all compounds with phenotype "stable", PUBCHEM_ACTIVITY_OUTCOME is "active". For all compounds with phenotype "unstable", PUBCHEM_ACTIVITY_OUTCOME is "inactive".
PhenotypeHalf-lifeAnalysis Comment
Unstable0.58Class=1
Unstable0.62Class=1
Unstable0.7Class=1
Unstable0.76Class=1
Unstable0.84Class=1
Unstable0.89Class=1
Unstable0.98Class=1
Unstable1Class=1
Unstable1Class=1
Unstable1.05Class=1
Unstable1.41Class=1
Unstable1.55Class=1
Unstable1.6Class=1
Unstable1.66Class=1
Unstable1.71Class=1
Unstable1.71Class=1
Unstable1.79Class=1
Unstable1.83Class=1
Unstable1.85Class=1
Unstable1.86Class=1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A7681
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Compounds dissolved in DMSO, and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073560 uMActivity at 0.0000367800 uMActivity at 0.0000735600 uMActivity at 0.0001677464 uMActivity at 0.0003678000 uMActivity at 0.0007363003 uMActivity at 0.00153 uMActivity at 0.00368 uMActivity at 0.00723 uMActivity at 0.00914 uMActivity at 0.018 uMActivity at 0.039 uMActivity at 0.092 uMActivity at 0.191 uMActivity at 0.460 uMActivity at 0.910 uMActivity at 1.182 uMActivity at 2.302 uMActivity at 4.834 uMActivity at 11.49 uMActivity at 23.94 uMActivity at 57.45 uMActivity at 115.4 uMActivity at 193.5 uMActivity at 288.3 uMCompound QC
Inhibitor1.0964121.524587Complete curve; high efficacy-5.960.60.996-99.00122.5235-1.10 0 0 0 0 0 0 0-91.416421.20118.089711.55633.2362-23.6097-54.3722-70.1237-91.4164QC'd by GVK
Inactive00041.30296.4095.7452-8.127411.434512.7995.91137.13891.3029QC'd by Vitas
Inhibitor0.05596.749490Complete curve; high efficacy-7.260.60.9836-74.157422.592-1.10 0 0 0 0 0 0 0-78.849512.345912.9899-11.4013-37.5586-53.042-61.5426-65.313-78.8495QC'd by Bosche
Inactive0004-9.339-4.094-2.86744.5071-4.4459-5.3433-2.46713.5091-9.339QC'd by BIOMOL
Inactive0-6.614.95490.77852.5-6.094140 0 0 0 0 0 0 1-8.7946-5.07-2.6335-5.97-10.49513.49112.05881.9174-8.7946QC'd by SIGMA
Inhibitor34.671339.82710Single point of activity-4.462.30310.825-41.327-1.5-30 0 0 0 0 0 0 0-31.93923.6009-5.26172.22954.1407-8.6455-6.9529-4.2362-31.9392QC'd by Microsource
Inactive040 0 0 0 0 0 0 0-13.898620.649216.42211.68939.501116.6467-2.6177-2.1673-13.8986QC'd by Vitas
Inhibitor15.487178.566741Partial curve; partial efficacy-4.810.80.995-76.6721.8947-2.20 0 0 0 0 0 0 0-58.08492.73420.67454.0214-0.609-3.975-12.9528-31.6593-58.0849QC'd by Sequoia
Inactive000426.644512.4429-0.644219.37847.33520.35134.22857.434426.6445QC'd by Microsource
Inactive0-5.92134.95490.79423.5-5.645240 0 0 0 0 0 1-9.4213-2.1113-8.4544-4.6822-8.22654.16062.7472-9.4213QC'd by Tocris
Inactive0004-2.8012-11.1342-2.1920-10.8176-0.6934-3.3166-1.4979-2.8012QC'd by SIGMA
Inactive0-5.764.95490.510428.8996-2.44840 1 0 0 0 0 0 1-2.30523.7377-36.8683-4.4543-19.5675-9.380122.243229.0984-2.305QC'd by Vitas
Inhibitor12.301887.401142Partial curve; high efficacy-4.910.60.9549-73.550113.8509-2.10 0 0 0 0 0 0 0-54.873522.14538.368412.13289.0141-1.3852-8.6537-22.9862-54.8735QC'd by Microsource
Inhibitor27.540450.239310Single point of activity-4.561.75290.9401-50.16480.0744-30 0 0 0 0 0 0 0-39.142.8036-3.03351.3596-6.01625.1159-1.7887-9.2175-39.14QC'd by Microsource
Inactive0-5.310.60.8041-16.01361740 0 0 0 0 0 0 0-11.67817.682513.435821.75976.519717.4375-0.6278-0.9036-11.678QC'd by Enzo
Inhibitor15.487177.547110Partial curve; partial efficacy; poor fit-4.811.1110.829-67.10610.4411-2.40 0 0 0 0 0 0 0-53.05410.743524.16552.70531.738225.7669-4.8999-19.2859-53.0541QC'd by Bosche
Inactive0-6.361.46410.8922-22.47584.540 0 0 0 0 0 0 0-25.49972.54256.30397.767-1.9911-6.3102-26.2299-15.2464-25.4997QC'd by Microsource
Inactive0-4.511.96730.4991426.540 0 0 0 0 0 0 016.846225.531732.670220.285228.569325.635926.981725.029716.8462QC'd by GVK
Inhibitor0.870947.278824Complete curve; partial efficacy-6.064.95490.9676-45.67661.6021-1.20 0 0 0 0 0 0 1-20.51278.27430.9756-1.5573-1.30970.8922-49.683-41.1152-20.5127QC'd by Enzo
Inactive0-6.064.95490.4399-0.676240 0 0 0 0 0 0 1-0.0131.95381.5464-4.31350.312-2.768216.93540.8252-0.013QC'd by Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: Basal_Viability_ATP_DLD-1_SP
Protocol: N/A
Comment: N/A
Activity at 0.2 uMActivity at 2 uMActivity at 20 uM
3.11.6-7.3
1.657.957.8
10.67.317.1
9.711.4-1.4
7.66.821.9
12.44758.1
1113.9-9.6
7.89.356.25
10.821.9
18.820.761
12.92.17.4
7.41.224.5
14.626.1726.9
14.814.6-1.7
12.815.4-3.5
8.28.8-17.7
11.611.7-8.3
26.559.5-3.05
14.215.8-6.9
12.430.8-2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-SARS-cytotox-48hr-p1-npc
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Dispense; 2 uL cells; white, 1536-well Greiner assay plate.
2; Incubate; 16 hr; 37 C, 5% CO2
3; Dispense; 23 nL; compounds in DMSO
4; Incubate; 1 hr; 37 C, 5% CO2
5; Dispense; 2 uL; media
6; Incubate; 48 hr; 37C, 5% CO2
7; Centrifuge; 10 sec; Blue Washer gentle centrifugation
8; Dispense; 4 uL; ATPLite reagent
9; Incubate; 5 min; room temperature
10; Read; Luminescence; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above)
1. Seed 1000 Vero E6 cells (ATCC #CRL-1586) in 2 uL/well media (EMEM 10% FetalClone II, 1x Pen/Strep) in white 1536-well assay plates (Greiner #782073).
2. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubate for 1 hr at 37C 5% CO2.
5. Dispense 2 uL/well of media (EMEM 10% FetalClone II, 1x Pen/Strep).
6. Incubate at for 48 hr at 37C 5% CO2.
7. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
8. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
9.Incubate for 5 min at room temperature.
10. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells containing media as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed apparent activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.104 uMActivity at 0.151 uMActivity at 0.229 uMActivity at 0.457 uMActivity at 0.573 uMActivity at 0.907 uMActivity at 1.145 uMActivity at 2.290 uMActivity at 3.065 uMActivity at 5.336 uMActivity at 6.860 uMActivity at 11.40 uMActivity at 15.33 uMActivity at 26.44 uMActivity at 34.30 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.5 uMActivity at 171.0 uMCompound QC
Inactive0004-4.2348000-4.2348QC'd by SIGMA
Inactive000400000QC'd by SIGMA
Inactive000400000QC'd by FLUKA
Inactive00040.2955-8.4544-0.071900.2955QC'd by SigmaAldrich
Inactive0-4.354.95490.7922-9.23891.540 0 0 0-6.8657004.5852-6.8657QC'd by SIGMA
Inactive00041.8364002.721.8364QC'd by Labotest
Inactive00041.8575004.55181.8575QC'd by SigmaAldrich
Inactive0004-1.7790-6.65020-1.779QC'd by SigmaAldrich
Cytotoxic5.623496.191184Complete curve; high efficacy-5.254.95490.9999-95.69110.5-1.10 0 0 0-96.07540.19610-92.9298-96.0754QC'd by Specs
Cytotoxic5.623490.58383Complete curve; high efficacy-5.254.95490.9987-88.5832-1.10 0 0 0-87.879903.2013-86.768-87.8799QC'd by Vitas
Cytotoxic0.707938.616166Complete curve; partial efficacy-6.153.990.9995-74.868-36.2519-1.20 0 0 0-75.3228-41.8999-74.8595-74.5922-75.3228QC'd by Sequoia
Cytotoxic3.5481102.204145Partial curve; high efficacy-5.454.50450.9986-99.70412.5-2.10 0 0 0-99.505104.1801-25.022-99.5051QC'd by SIGMA
Cytotoxic8.912582.729443Partial curve; high efficacy-5.051.55790.9999-91.2905-8.5611-2.10 0 0 0-87.443-9.2176-17.4332-57.2315-87.443QC'd by SigmaAldrich
Cytotoxic7.943395.366643Partial curve; high efficacy-5.11.34430.9999-95.7901-0.4234-2.10 0 0 0-89.19-2.0195-15.8041-59.401-89.19QC'd by Bosche
Cytotoxic14.125499.693742Partial curve; high efficacy-4.852.72020.9996-98.69371-2.10 0 0 0-96.758501.5165-34.3212-96.7585QC'd by NCI
Cytotoxic1095.453642Partial curve; high efficacy-53.92950.9998-96.4536-1-2.10 0 0 0-96.26110-1.9942-60.9288-96.2611QC'd by Microsource
Cytotoxic1063.467342Partial curve; partial efficacy-53.1320.9999-62.96730.5-2.20 0 0 0-62.690600-37.6527-62.6906QC'd by APExBIO
Cytotoxic8.912571.983342Partial curve; partial efficacy-5.054.0951-71.98330-2.20 0 0 0-71.915100-52.954-71.9151QC'd by Sequoia
Cytotoxic14.125483.876341Partial curve; partial efficacy-4.851.92820.9988-79.87634-2.20 0 0 0-74.88544.84030-28.1646-74.8854QC'd by Vitas
Cytotoxic22.3872106.157741Partial curve; high efficacy-4.652.24810.999-102.15774-2.10 0 0 0-90.56532.21854.8235-14.3188-90.5653QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: GPx1-biochemical-p4-p7
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent 1; 3 uL; GPx1 enzyme or no enzyme control in 1536-well, black, solid Greiner assay plate.
2; Compound; 25 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head.
3; Incubation; 30 min; room temperature.
4; Reagent 2; 1 uL; 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA substrate
5; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.
6; Incubation; 15 min; room temperature.
7; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.

NOTES (numbers refer to Sequence numbers above)
1. 3 uL of 16.66 nM GPX1 and 0.016% BSA in assay buffer (50 mM Tris-HCl, 2 mM EDTA (pH 7.5), 150 mM NaCl) was added to columns 3-48 of 1536-well assay plates using a BioRAPTR Flying Reagent Dispenser (Let's Go Robotics (LGR), Carlsbad, CA). A no-enzyme control (0.01% BSA in TES assay buffer) was added to columns 1-2.
2. 25 nL of test compounds and DMSO controls were added to each well with a pin tool (Kalypsys).
3. The assay plates were incubated for 30 minutes at room temperature.
4. 1 uL of master mix (500 nM glutathione reductase (GR), 5 mM reduced glutathione (GSH), 2.5 mM NADPH in assay buffer) was added. 1 uL of cumene hydroperoxide (CHP) ([2.5 mM] in 50% EtOH) was then added within 5 minutes to initiate the reaction. Final concentrations were: 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA.
5. Initial fluorescence readout (t=0) at 340/450 nm was measured using a ViewLux multimodal detector (PerkinElmer, Waltham, MA).
7. Endpoint fluorescence readout (t=15) at 340/450 nm was measured 15 min after room temperature incubation.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000080000 uMActivity at 0.0000294000 uMActivity at 0.0000322389 uMActivity at 0.0000640000 uMActivity at 0.0001602685 uMActivity at 0.0003305803 uMActivity at 0.0007029698 uMActivity at 0.00145 uMActivity at 0.00305 uMActivity at 0.00484 uMActivity at 0.00883 uMActivity at 0.016 uMActivity at 0.036 uMActivity at 0.076 uMActivity at 0.127 uMActivity at 0.227 uMActivity at 0.400 uMActivity at 1.089 uMActivity at 1.958 uMActivity at 4.491 uMActivity at 9.517 uMActivity at 15.29 uMActivity at 27.66 uMActivity at 48.83 uMActivity at 98.28 uMActivity at 150.0 uMCompound QC
Inhibitor1.153584.01186Complete curve; high efficacy-5.9382.95230.9935-85.511-1.5-1.10 0 0 0 0 0 1000.55170-10.1942-66.3862-86.37470QC'd by MedChem Express
Inhibitor4.0381107.130985Complete curve; high efficacy-5.39381.10.9833-107.6309-0.5-1.10 0 0 0 0 0 0-99.10763.0643-3.35612.7295-17.6643-28.702-81.8703-99.1076QC'd by Prestwick
Inhibitor4.5309100.661985Complete curve; high efficacy-5.34381.46410.9928-111.2365-10.5746-1.10 0 0 0 0 0 0-102.4277-6.7289-14.1368-11.7774-11.5064-34.358-88.9997-102.4277QC'd by Glixx
Inhibitor3.207694.995685Complete curve; high efficacy-5.49381.69240.997-110.0264-15.0308-1.10 0 0 0 0 0 0-108.5073-10.859-15.7072-17.8113-19.7979-44.1871-99.3353-108.5073QC'd by MedChem Express
Inhibitor3.207694.333585Complete curve; high efficacy-5.49381.55790.9917-98.6297-4.2962-1.10 0 0 0 0 0 0-97.268-10.9671-0.2469-8.8219-8.6028-35.074-85.0291-97.268QC'd by Vitas
Inhibitor4.0381101.224485Complete curve; high efficacy-5.39382.24810.9999-101.22440-1.10 0 0 0 0 0 0-101.0224000.6663-1.57-17.0563-89.6716-101.0224QC'd by DC Chemicals
Inhibitor4.5309102.529384Complete curve; high efficacy-5.34381.88510.9958-104.0293-1.5-1.10 0 0 0 0 0 0-100.803500-6.96670.0183-19.6985-87.3271-100.8035QC'd by MedChem Express
Inhibitor5.152590.153784Complete curve; high efficacy-5.2881.96730.9895-98.5024-8.3487-1.10 0 0 0 0 0 0-96.571-12.4368-8.9031-14.8602-3.6239-19.2852-77.5914-96.571QC'd by EMD Chemicals
Inhibitor6.496.476183Complete curve; high efficacy-5.19383.92950.9988-94.97611.5-1.10 0 0 0 0 0 0-95.357503.3535002.0026-79.8012-95.3575QC'd by Microsource
Inhibitor6.489.09983Complete curve; high efficacy-5.19384.44950.9997-88.5990.5-1.10 0 0 0 0 0 0-88.422200.5042.224300-77.8921-88.4222QC'd by SigmaAldrich
Inhibitor4.0928572.588765Partial curve; high efficacy-5.3882.90231-572.58870-2.10 0 0 0 0 0 100000-52.3008-521.48330QC'd by Microsource
Inhibitor2.547977.642365Complete curve; partial efficacy-5.59384.50450.9919-92.3162-14.6738-1.20 0 0 0 0 0 0-90.5524-12.7147-12.5699-11.8115-21.2763-34.6101-93.8172-90.5524QC'd by SIGMA
Inhibitor2.023979.203365Complete curve; partial efficacy-5.69381.1110.9975-92.0986-12.8952-1.20 0 0 0 0 0 0-89.2428-13.3008-14.4831-11.996-25.7417-51.5286-82.1843-89.2428QC'd by SIGMA
Inhibitor2.547939.753164Complete curve; partial efficacy-5.59384.50450.9617-72.8813-33.1282-1.20 0 0 0 0 0 0-68.5285-37.2443-35.4912-31.4131-28.8568-43.7703-77.3346-68.5285QC'd by Microsource
Inhibitor5.7812259.6350Partial curve; high efficacy-5.2381.69240.9999-259.630-2.10 0 0 0 0 0 0-250.1252000-1.0316-34.0768-179.1962-250.1252QC'd by Adooq
Inhibitor4.0928222.462650Partial curve; high efficacy-5.3882.58840.9995-221.46261-2.10 0 0 0 0 0 100003.8047-24.8352-196.33210QC'd by Glixx
Inhibitor18.0377742.537649Partial curve; high efficacy-4.74382.72021-741.53761-2.10 0 0 0 0 0 0-698.2464003.833500-124.2034-698.2464QC'd by Vitas
Inhibitor16.0761622.503649Partial curve; high efficacy-4.79382.25261-622.50360-2.10 0 0 0 0 0 0-576.39220000-5.8017-157.3588-576.3922QC'd by Glixx
Inhibitor16.0761415.830746Partial curve; high efficacy-4.79382.25260.9995-418.3307-2.5-2.10 0 0 0 0 0 0-387.3433-6.004500-3.7575-3.0222-113.565-387.3433QC'd by SIGMA
Inhibitor16.2936426.190146Partial curve; high efficacy-4.7882.72020.9998-425.69010.5-2.10 0 0 0 0 0 0-400.838100003.5739-74.4409-400.8381QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-MERS-PP-p1-npc
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Dispense; 2 uL cells; white, 1536-well Greiner assay plate.
2; Incubate; 16 hr; 37C, 5% CO2
3; Dispense; 23 nL; compounds in DMSO
4; Incubate; 1 hr; 37C, 5% CO2
5; Dispense; 2 uL; SARS-S MLVpp
6; Centrifuge; 45 min; 1500 rpm, room temperature
7; Incubate; 48 hr; 37C, 5% CO2
8; Centrifuge; 10 sec; Blue Washer gentle centrifugation
9; Dispense; 4 uL; Bright-Glo Luciferase reagent
10; Incubate; 5 min; room temperature
11; Read; Luminescence; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above)
1. Seed 2000 Huh7 cells (JCRB cell bank # JCRB0403) in 2 microL/well media (DMEM 10% FetalClone II, 1x Pen/Strep) in white 1536-well assay plates (Greiner #782073).
2. Incubate at 37 degrees C with 5% CO2 overnight (~16 h).
3. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubate for 1 h at 37C 5% CO2.
5. Dispense 2 microL/well of MERS-S pseudotyped particles (MERS-S MLVpp).
6. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubate at for 48 h at 37C 5% CO2.
8. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Dispense 4 microL/well of Bright-Glo Luciferase detection reagent (Cat#E2620, Promega).
10. Incubate for 5 min at room temperature.
11. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing MERS-S MLVpp as 100%, and wells containing control MLVpp (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.104 uMActivity at 0.151 uMActivity at 0.229 uMActivity at 0.457 uMActivity at 0.573 uMActivity at 0.907 uMActivity at 1.145 uMActivity at 2.290 uMActivity at 3.065 uMActivity at 5.336 uMActivity at 6.860 uMActivity at 11.40 uMActivity at 15.33 uMActivity at 26.44 uMActivity at 34.30 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.5 uMActivity at 171.0 uMCompound QC
Inhibitor196.333987Complete curve; high efficacy-64.95490.9998-94.33392-1.10 0 0 0-94.71280-92.7751-93.4163-94.7128QC'd by Labotest
Inhibitor0.891383.712687Complete curve; high efficacy-6.052.78680.9996-96.241-12.5283-1.10 0 0 0-96.6275-23.7736-90.8469-95.0049-96.6275QC'd by Microsource
Inhibitor1.258996.405987Complete curve; high efficacy-5.93.67720.9999-94.40592-1.10 0 0 0-94.7850-85.1427-94.1736-94.785QC'd by MedChem Express
Inhibitor1.995395.447386Complete curve; high efficacy-5.73.1321-95.44730-1.10 0 0 0-95.25680-13.739-92.0399-95.2568QC'd by Vitas
Inhibitor3.548197.463985Complete curve; high efficacy-5.454.0950.9999-96.96390.5-1.10 0 0 0-96.77030-13.1147-96.7363-96.7703QC'd by Vitas
Inhibitor2.511983.527785Complete curve; high efficacy-5.62.04790.9986-97.9692-14.4414-1.10 0 0 0-97.1916-15.3679-54.1106-93.8954-97.1916QC'd by Selleck
Inhibitor3.548195.216485Complete curve; high efficacy-5.451.34430.9998-100.6043-5.3878-1.10 0 0 0-99.2152-11.1565-39.2196-83.7948-99.2152QC'd by Microsource
Inhibitor5.623495.304384Complete curve; high efficacy-5.254.95490.9998-94.80430.5-1.10 0 0 0-94.05190.12070-92.6695-94.0519QC'd by NCI
Inhibitor4.466884.504484Complete curve; high efficacy-5.351.28760.9998-86.2923-1.788-1.10 0 0 0-82.6781-5.6567-27.5762-66.8514-82.6781QC'd by Microsource
Inhibitor5.623494.308284Complete curve; high efficacy-5.254.95490.9999-93.80820.5-1.10 0 0 0-93.620900-91.0139-93.6209QC'd by Microsource
Inhibitor5.011995.787984Complete curve; high efficacy-5.34.95490.9998-94.78791-1.10 0 0 0-94.598700-93.6402-94.5987QC'd by Microsource
Inhibitor7.079597.850183Complete curve; high efficacy-5.154.50450.9989-95.85012-1.10 0 0 0-96.23503.6521-85.6349-96.235QC'd by SigmaAldrich
Inhibitor7.0795100.26783Complete curve; high efficacy-5.154.95490.9991-98.7671.5-1.10 0 0 0-97.983103.2082-91.1572-97.9831QC'd by Vitas
Inhibitor8.912593.906183Complete curve; high efficacy-5.054.95490.9997-93.90610-1.10 0 0 0-93.160800-73.8376-93.1608QC'd by Prestwick
Inhibitor7.943389.629783Complete curve; high efficacy-5.14.50451-89.62970-1.10 0 0 0-89.450800-75.1088-89.4508QC'd by Microsource
Inhibitor0.794367.818568Complete curve; partial efficacy-6.11.62590.9992-98.2669-30.4484-1.20 0 0 0-98.6616-49.9386-88.086-96.3968-98.6616QC'd by Selleck
Inhibitor0.891367.063767Complete curve; partial efficacy-6.053.51170.9999-94.9798-27.9161-1.20 0 0 0-95.3612-33.7668-92.536-94.9745-95.3612QC'd by SIGMA
Inhibitor0.891374.058867Complete curve; partial efficacy-6.052.78680.9997-93.5396-19.4808-1.20 0 0 0-94.4845-29.5673-88.416-93.2736-94.4845QC'd by MedChem Express
Inhibitor2.818472.588465Complete curve; partial efficacy-5.552.40640.9994-99.8255-27.2371-1.20 0 0 0-99.0333-28.5309-54.1516-98.53-99.0333QC'd by GVK
Inhibitor3.548147.271765Complete curve; partial efficacy-5.452.12110.9998-98.6785-51.4068-1.20 0 0 0-98.4816-51.7655-65.2319-95.3281-98.4816QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-MERS-cytotox-48hr-p1-npc
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Dispense; 2 uL cells; white, 1536-well Greiner assay plate.
2; Incubate; 16 hr; 37C, 5% CO2
3; Dispense; 23 nL; compounds in DMSO
4; Incubate; 1 hr; 37C, 5% CO2
5; Dispense; 2 uL; media
6; Incubate; 48 hr; 37C, 5% CO2
7; Centrifuge; 10 sec; Blue Washer gentle centrifugation
8; Dispense; 4 uL; ATPLite reagent
9; Incubate; 5 min; room temperature
10; Read; Luminescence; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above)
1. Seed 2000 Huh7 cells (JCRB cell bank # JCRB0403) in 2 uL/well media (DMEM 10% FetalClone II, 1x Pen/Strep) in white 1536-well assay plates (Greiner #782073).
2. Incubate at 37C with 5% CO2 overnight (~16 h).
3. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubate for 1 hr at 37C 5% CO2.
5. Dispense 2 uL/well of media (DMEM 10% FetalClone II, 1x Pen/Strep).
6. Incubate at for 48 hr at 37C 5% CO2.
7. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
8. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
9. Incubate for 5 min at room temperature.
10. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells containing media as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no apparent activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.104 uMActivity at 0.151 uMActivity at 0.229 uMActivity at 0.457 uMActivity at 0.573 uMActivity at 0.907 uMActivity at 1.145 uMActivity at 2.290 uMActivity at 3.065 uMActivity at 5.336 uMActivity at 6.860 uMActivity at 11.40 uMActivity at 15.33 uMActivity at 26.44 uMActivity at 34.30 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.5 uMActivity at 171.0 uMCompound QC
Cytotoxic3.162391.43685Complete curve; high efficacy-5.53.92950.9999-96.4465-5.0105-1.10 0 0 0-96.1361-4.5921-25.7892-96.254-96.1361QC'd by Labotest
Cytotoxic3.981195.751784Complete curve; high efficacy-5.44.50450.9999-95.75170-1.10 0 0 0-95.19320-7.5797-95.5606-95.1932QC'd by Microsource
Cytotoxic1.258940.731466Complete curve; partial efficacy-5.91.210.9997-86.599-45.8676-1.20 0 0 0-85.9117-55.1995-73.2026-84.1817-85.9117QC'd by Enzo
Cytotoxic8.912598.06743Partial curve; high efficacy-5.053.06540.9999-97.5670.5-2.10 0 0 0-95.094600.6077-19.7721-95.0946QC'd by Tocris
Cytotoxic10105.244942Partial curve; high efficacy-51.13410.9999-99.74495.5-2.10 0 0 0-87.03751.9925-11.2908-50.5231-87.0375QC'd by SigmaAldrich
Cytotoxic7.079574.189742Partial curve; partial efficacy-5.151.210.9998-75.7999-1.6102-2.20 0 0 0-69.9242-3.8419-17.0574-49.2901-69.9242QC'd by Sequoia
Cytotoxic1082.250142Partial curve; high efficacy-52.78680.9996-81.25011-2.10 0 0 0-80.921200-46.8123-80.9212QC'd by Bosche
Cytotoxic11.220270.751442Partial curve; partial efficacy-4.953.1320.9997-70.75140-2.20 0 0 0-69.677300-36.9652-69.6773QC'd by Vitas
Cytotoxic11.220267.55142Partial curve; partial efficacy-4.952.40640.9997-67.5510-2.20 0 0 0-65.83420-1.4108-35.2917-65.8342QC'd by Sequoia
Cytotoxic7.943373.080642Partial curve; partial efficacy-5.11.22210.9998-71.08062-2.20 0 0 0-64.74650-11.4632-42.9379-64.7465QC'd by Microsource
Cytotoxic22.387277.777441Partial curve; partial efficacy-4.652.12111-77.77740-2.20 0 0 0-68.3920-0.4599-15.1027-68.392QC'd by Enzo
Cytotoxic12.589369.025841Partial curve; partial efficacy-4.91.98870.9999-66.02583-2.20 0 0 0-62.98692.81820.7552-27.7994-62.9869QC'd by Microsource
Cytotoxic19.952672.771641Partial curve; partial efficacy-4.72.04790.9998-72.27160.5-2.20 0 0 0-64.599700-16.6801-64.5997QC'd by Prestwick
Cytotoxic28.1838115.995140Partial curve; high efficacy-4.552.24810.9999-115.49510.5-2.10 0 0 0-95.767100-12.122-95.7671QC'd by Sequoia
Cytotoxic31.622866.021240Partial curve; partial efficacy-4.54.95490.9998-66.02120-2.20 0 0 0-65.808100-10.4112-65.8081QC'd by AKos
Cytotoxic28.1838106.765440Partial curve; high efficacy-4.552.24811-106.76540-2.10 0 0 0-88.528500-12.0122-88.5285QC'd by Toronto Research
Cytotoxic31.6228126.820340Partial curve; high efficacy-4.52.04371-126.32030.5-2.10 0 0 0-97.02020.59490-13.8992-97.0202QC'd by Selleck
Cytotoxic2.511946.556323Complete curve; partial efficacy-5.61.13410.9987-46.40310.1532-1.20 0 0 0-45.0904-4.8723-22.5413-38.9308-45.0904QC'd by Sequoia
Cytotoxic2.238743.954323Complete curve; partial efficacy-5.651.41630.9994-48.3722-4.4179-1.20 0 0 0-48.5721-8.6816-27.0016-44.0154-48.5721QC'd by Vitas
Cytotoxic1.258951.932623Complete curve; partial efficacy-5.92.63840.9993-48.43263.5-1.20 0 0 0-49.01170-39.4678-47.3958-49.0117QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: TRND-SARS-PP-p1-npc
Protocol: Protocol:
PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Dispense; 2 uL cells; white, 1536-well Greiner assay plate.
2; Incubate; 16 hr; 37 C, 5% CO2
3; Dispense; 23 nL; compounds in DMSO
4; Incubate; 1 hr; 37 C, 5% CO2
5; Dispense; 2 uL; SARS-S MLVpp
6; Centrifuge; 45 min; 1500 rpm, room temperature
7; Incubate; 48 hr; 37C, 5% CO2
8; Centrifuge; 10 sec; Blue Washer gentle centrifugation
9; Dispense; 4 uL; Bright-Glo Luciferase reagent
10; Incubate; 5 min; room temperature
11; Read; Luminescence; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above)
1. Seed 2000 Vero E6 cells (ATCC #CRL-1586) in 2 uL/well media (EMEM 10% FetalClone II, 1x Pen/Strep) in white 1536-well assay plates (Greiner #782073).
2. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubate for 1 hr at 37C 5% CO2.
5. Dispense 2 uL/well of SARS-S pseudotyped particles (SARS-S MLVpp).
6. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubate at for 48 hr at 37C 5% CO2.
8. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Dispense 4 uL/well of Bright-Glo Luciferase detection reagent (Promega #E2620).
10. Incubate for 5 min at room temperature.
11. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing SARS-S MLVpp as 100%, and wells containing control MLVpp (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.104 uMActivity at 0.151 uMActivity at 0.229 uMActivity at 0.457 uMActivity at 0.573 uMActivity at 0.907 uMActivity at 1.145 uMActivity at 2.290 uMActivity at 3.065 uMActivity at 5.336 uMActivity at 6.860 uMActivity at 11.40 uMActivity at 15.33 uMActivity at 26.44 uMActivity at 34.30 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.5 uMActivity at 171.0 uMCompound QC
Inhibitor197.380287Complete curve; high efficacy-61.37230.9991-99.9438-2.5636-1.10 0 0 0-99.1506-27.553-75.0674-97.7163-99.1506QC'd by Microsource
Inhibitor1.412598.888487Complete curve; high efficacy-5.853.24750.9999-96.38842.5-1.10 0 0 0-96.77550-80.0472-95.8934-96.7755QC'd by Labotest
Inhibitor1.4125101.075287Complete curve; high efficacy-5.854.44950.9999-97.57523.5-1.10 0 0 0-97.96712.8759-86.7011-96.8007-97.9671QC'd by Labotest
Inhibitor1102.246387Complete curve; high efficacy-64.0950.9999-98.24634-1.10 0 0 0-98.64090-94.9201-97.3825-98.6409QC'd by Selleck
Inhibitor1100.87687Complete curve; high efficacy-62.04370.9997-97.58233.2937-1.10 0 0 0-97.9742-13.5052-82.6458-96.1026-97.9742QC'd by Microsource
Inhibitor2.238793.908186Complete curve; high efficacy-5.651.96730.9988-99.4111-5.503-1.10 0 0 0-98.0385-9.5858-51.8655-97.2234-98.0385QC'd by SIGMA
Inhibitor2.818497.821885Complete curve; high efficacy-5.552.72020.9992-96.82181-1.10 0 0 0-95.71360-33.6037-96.6286-95.7136QC'd by NCI
Inhibitor3.162382.273885Complete curve; high efficacy-5.52.84730.9999-99.8849-17.6111-1.10 0 0 0-99.6855-18.0092-40.9738-98.4052-99.6855QC'd by Vitas
Inhibitor3.548188.764685Complete curve; high efficacy-5.452.95230.9987-97.5643-8.7996-1.10 0 0 0-99.1507-8.1663-29.4656-93.2495-99.1507QC'd by Glixx
Inhibitor3.162399.786485Complete curve; high efficacy-5.52.47290.9993-99.78640-1.10 0 0 0-98.40860-32.3549-96.4346-98.4086QC'd by MedChem Express
Inhibitor3.548191.741984Complete curve; high efficacy-5.452.35310.9997-93.2919-1.55-1.10 0 0 0-93.6666-1.7084-26.6215-87.3985-93.6666QC'd by SIGMA
Inhibitor5.623498.837884Complete curve; high efficacy-5.254.95491-98.83780-1.10 0 0 0-98.64050-1.6294-96.1264-98.6405QC'd by Microsource
Inhibitor3.981197.129584Complete curve; high efficacy-5.44.50451-97.12950-1.10 0 0 0-97.51960-7.4315-96.036-97.5196QC'd by Microsource
Inhibitor0.891374.188768Complete curve; partial efficacy-6.053.19250.9999-97.3803-23.1916-1.20 0 0 0-97.7714-30.993-94.0197-96.8652-97.7714QC'd by ChemDiv
Inhibitor0.794377.951768Complete curve; partial efficacy-6.14.44950.9989-96.4651-18.5134-1.20 0 0 0-96.8525-24.5945-96.6992-94.6899-96.8525QC'd by SIGMA
Inhibitor0.891362.381668Complete curve; partial efficacy-6.053.1320.9999-97.0294-34.6478-1.20 0 0 0-97.4191-41.2998-94.2087-97.0954-97.4191QC'd by MedChem Express
Inhibitor3.162364.840865Complete curve; partial efficacy-5.53.24750.9993-96.5147-31.6739-1.20 0 0 0-95.2478-31.8116-48.6639-96.3221-95.2478QC'd by Prestwick
Inhibitor8.912596.79743Partial curve; high efficacy-5.054.0950.9999-96.7970-2.10 0 0 0-97.185800-70.4182-97.1858QC'd by Sequoia
Inhibitor12.589399.308542Partial curve; high efficacy-4.92.40640.9995-98.30851-2.10 0 0 0-96.380900-41.6052-96.3809QC'd by Tocris
Inhibitor14.125493.017342Partial curve; high efficacy-4.851.69240.9985-94.0173-1-2.10 0 0 0-87.0530-7.0161-38.4623-87.053QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: WntCondMedia_bCateninfluor/nucareaC2C12_SP
Protocol: N/A
Comment: N/A
Activity at 2 uMActivity at 10 uM
-2.51.5
2.93.4
-0.60.8
-1.6-0.2
1.43.2
-1.4-0.8
1.90.1
1.10.4
-0.23.2
0.42.5
-0.90.2
2.2-0.4
0.1-0.3
-0.80.5
0.51.4
-0.1-1
-21
0.33.1
-1.7-1.5
-2.3-0.4